Safety and efficacy of mitemcinal fumarate (GM-611) in diabetic gastroparesis: 12-week, multi-center, double-blind, placebo-contolled, phase 2b study (GM-611-05)

被引：0
|
作者：
Faichney, JD
Goldstein, BJ
Fogel, RP
Mccallum, RW
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A512 / A512
页数：1
相关论文
共 33 条
  • [1] Mitemcinal fumarate (GM-611) provided symptomatic relief of diabetic gastroparesis, especially in type 1 diabetes: Results of a 12-week, multi-center, double-blind, placebo-controlled, randomized phase 2B study (GM-611-05)
    McCallum, RW
    Fogel, R
    Fang, JC
    Altman, RS
    Faichney, JD
    Goldstein, BJ
    GASTROENTEROLOGY, 2005, 128 (04) : A467 - A467
  • [2] Diabetic gastroparesis: Effect of mitemcinal by subgroup analysis in a 12-week, randomized, multi-center, double-blind, placebo-controlled, phase 2b study
    McCallum, Richard W.
    Goldstein, Barry J.
    GASTROENTEROLOGY, 2006, 130 (04) : A598 - A598
  • [3] RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS: EFFICACY AND SAFETY RESULTS FROM A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY (RM-131-009)
    Camilleri, Michael
    McCallum, Richard W.
    Tack, Jan F.
    Spence, Sharon C.
    Gottesdiener, Keith
    Fiedorek, Fred T.
    GASTROENTEROLOGY, 2017, 152 (05) : S139 - S140
  • [4] A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis
    Abell, Thomas L.
    Kuo, Braden
    Esfandyari, Tuba
    Pfeifer, Nathan D.
    Grimaldi, Maria
    Renzulli, Cecilia
    Tacchi, Raffaella
    Zhou, Kefei
    Barnes, Chris N.
    Nguyen, Deanna D.
    Nguyen, Linda
    Talley, Nicholas J.
    McCallum, Richard
    NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (04):
  • [5] Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis
    McCallum, R. W.
    Lembo, A.
    Esfandyari, T.
    Bhandari, B. R.
    Ejskjaer, N.
    Cosentino, C.
    Helton, N.
    Mondou, E.
    Quinn, J.
    Rousseau, F.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2013, 25 (11): : E705 - E717
  • [6] Eliapixant in Refractory Chronic Cough: The 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2b PAGANINI Study
    Dicpinigaitis, P.
    Morice, A. H.
    Smith, J.
    Sher, M. R.
    Vaezi, M.
    Guilleminault, L.
    Niimi, A.
    Krahn, U.
    Saarinen, R.
    Pires, P. Vieira
    Wosnitza, M.
    Mcgarvey, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [7] Efficacy and Safety of Tenapanor in Patients With Constipation Predominant Irritable Bowel Syndrome: A 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2B Trial
    Chey, William D.
    Lembo, Anthony
    Phillips, James A.
    Rosenbaum, David P.
    GASTROENTEROLOGY, 2015, 148 (04) : S191 - S192
  • [8] A 12-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase-2, Dose Selection Study of Lorcaserin Hydrochloride for Smoking Cessation: Preliminary Report
    Wilcox, Charles
    Tong, My-Linh
    Oskooilar, Nader
    Morrissey, Judy
    De Francisco, Don
    Henry, Mellissa
    Badgett, Lynn
    Grosz, Daniel
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S626 - S627
  • [9] A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY OF ENCENICLINE OR PLACEBO IN SCHIZOPHRENIA SUBJECTS ON CHRONIC STABLE ATYPICAL ANTIPSYCHOTIC THERAPY
    Lombardo, I.
    Dgetluck, N.
    Hilt, D.
    Koenig, G.
    Loewen, G.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S322
  • [10] A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
    Wei, J. C. C.
    Fleischmann, R. M.
    Morris, S.
    Polvent, E.
    Shen, Z.
    Roche, A. Clouser
    Hingorani, V.
    Yan, S.
    Yeh, L. T.
    Keenan, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 192 - 192
1234